Home › Compare › AECLY vs ABBV
AECLY yields 3.44% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, AECLY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AECLY + ABBV for your $10,000?
AECI Ltd, together with its subsidiaries, engages in the mining, water treatment, plant and animal health, food and beverage, infrastructure, and general industrial sectors in Africa, Europe, Southeast Asia, North America, South America, and Australia. The company operates through five segments: AECI Mining, AECI Water, AECI Agri Health, AECI Chemicals, and AECI Property Services & Corporate. The AECI Mining segment provides mine-to-mineral solution for the mining sector, which includes commercial explosives, initiating systems, and blasting services, as well as surfactants for explosives manufacture. The AECI Water segment provides integrated water treatment and process chemicals, and equipment solutions for various applications comprising public and industrial water, desalination, and utilities. The AECI Agri Health segment manufactures and distributes crop protection products, plant nutrients, animal premixes, specialty animal health products, and fine chemicals. The AECI Chemicals segment supplies raw materials and related services to customers in the food and beverage, manufacturing, road infrastructure, and general industrial sectors. The AECI Property Services & Corporate segment offers property leasing and management services in the office, industrial, and retail sectors. The company was founded in 1894 and is based in Sandton, South Africa.
Full AECLY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.